Background: Malignant neoplasms is the second most common non-SSc associated cause of death in SSc patients, only second to infection. And among all the neoplasms, lung cancers are the most common, which is in the urgent need of attention from clinicians.

Objectives: To analyze the clinical features of patients of SSc with lung cancer.

Methods: Medical records of inpatients admitted in Peking Union Medical College Hospital from March 1992 to December 2018, were collected and analyzed, including the clinical manifestation, laboratory data, radiological images, pathology. SSc patients without lung cancer during the same period, matched by age and gender, were selected as the controls.

Results: Nineteen SSc patients with complete medical records were identified, with 17 (89.5%) females and 2 (10.5%) males. The mean age of SSc onset was 37.8±12.0 years old and of lung cancer diagnosis was (54.4±10.2) years old. One (5.3%) had a smoking history. Eight (42.1%) patients had family history of cancer, which was significantly higher than those without lung cancer (4 patients, 5.3%, P<0.001). The proportion of limited cutaneous SSc (lcSSc) were 63.2% among these cases, 7 patients had resolution of ReA; 2 had relapsing courses and 1 persistent arthritis. Four were in remission off all drugs. Controls had similar proportions. All patients developed lung cancer after the diagnosis of SSc, with a median interval 10.5 (range 2.0-36.2) years. In most of them (18, 94.7%), the difference between the two groups was not statistically significant (P = 0.259 and 0.051, respectively).

Conclusion: It is not uncommon that SSc could be concomitant with lung cancer, especially for those with long disease duration and family history of malignancy. Due to the subtle onset of lung cancer, clinicians should pay attention to it during clinical practice.

References:

Disclosure of Interests: Hui Zhong: None declared, Xiaoxin Zhou: None declared, Shangzhu Zhang: None declared, Yan Xu: None declared, Yong Hou: None declared, Mengtao Li: None declared, Dong Xu: None declared, Mengzhao Wang: None declared, Xiaofeng Zeng Consultant of: MSD Pharmaceuticals
DOI: 10.1136/annrheumdis-2020-eular.5163